Figure 1.
PFS and OS in all 583 patients. Kaplan-Meier curves estimating the PFS (A), OS (B), and PFS according to EGFR mutation type (C), and OS according to EGFR mutation type (D). PFS and OS was determined starting from the date of osimertinib treatment. CI, confidence interval; Ex 21, exon 21; Exon 19 del, Exon 19 deletion; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.